Cencora, Inc. $COR Shares Bought by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 46.8% during the 1st quarter, HoldingsChannel reports. The firm owned 63,926 shares of the company’s stock after buying an additional 20,374 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Cencora were worth $20,082,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Diversified Trust Co raised its position in shares of Cencora by 0.7% in the first quarter. Diversified Trust Co now owns 33,469 shares of the company’s stock valued at $10,514,000 after buying an additional 233 shares during the last quarter. Nations Financial Group Inc. IA ADV boosted its position in Cencora by 2.0% during the first quarter. Nations Financial Group Inc. IA ADV now owns 19,061 shares of the company’s stock worth $5,988,000 after acquiring an additional 369 shares during the last quarter. J. Derek Lewis & Associates Inc. acquired a new position in Cencora during the fourth quarter worth about $263,000. Stance Capital LLC purchased a new stake in Cencora during the 4th quarter valued at about $3,414,000. Finally, Rockefeller Capital Management L.P. raised its holdings in Cencora by 43.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 197,430 shares of the company’s stock valued at $66,682,000 after acquiring an additional 59,408 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.1%

NYSE COR opened at $271.99 on Friday. The firm’s 50-day moving average is $284.59 and its two-hundred day moving average is $324.35. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The stock has a market capitalization of $52.92 billion, a P/E ratio of 20.86, a PEG ratio of 1.47 and a beta of 0.59.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same period last year, the business earned $4.42 EPS. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, sell-side analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora announced that its Board of Directors has initiated a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on COR shares. Wells Fargo & Company decreased their target price on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. William Blair assumed coverage on Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating for the company. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. UBS Group increased their price target on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Morgan Stanley set a $342.00 price objective on Cencora in a research note on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus price target of $374.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.